Fact Source: Financial Supervisory Service DART / 2025-03-31
Disclosure Type: Execution of Single Sales/Supply Contract (Amendment)
💡 3-Second Summary
SAMSUNG BIOLOGICS has successfully fulfilled its long-term contract manufacturing organization (CMO) agreement active since 2016 with global pharmaceutical firm Cilag GmbH International, fully lifting the confidentiality veil to reveal the client’s identity and final timeline.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Reason for Amendment: Disclosure of the final contract expiration date and lift of operational confidentiality due to full project completion.
- Counterparty: Cilag GmbH International
- Final Confirmed Contract Value: KRW 436,017,975,914 (KRW 436B)
- Value Adjustment Details: Increased by USD 81,259,297.76 from the previous USD 291,788,251.79 at the client’s request, reaching a final confirmed total of USD 373,047,549.55.
- Applied Exchange Rate: Fixed at the initial base rate of USD/KRW 1,168.80 as of November 16, 2016 (the initial filing date).
- Ratio to Revenue at Initial Filing: 477.68% (Compared against the fiscal year 2015 revenue of KRW 91,278,028,788 right before the initial disclosure).
- Final Contract Period: From November 15, 2016, to March 31, 2025 (Approximately 8 years and 4 months).
- Amendments Made: Advanced the confidentiality expiration date from December 31, 2025, to the actual completion date of March 31, 2025, converting all masked information into full transparency.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This amendment filing serves as a substantial validation of SAMSUNG BIOLOGICS’ fundamental execution capability and long-term institutional track record. Seamlessly fulfilling a major operational supply commitment spanning over eight years highlights the company’s manufacturing stability, regulatory compliance, and robust pipeline management.
From a balance sheet perspective, the critical detail is the progressive upscaling of the contract value. Rather than simply concluding the deal, the final metrics show an expansion of approximately USD 81.25 million driven by client orders during the life cycle. This indicates that client satisfaction remained high enough to channel additional volume expansions into SAMSUNG BIOLOGICS’ facility lines.
Unmasking the counterparty as Cilag GmbH International—a premier international drug-manufacturing subsidiary of Johnson & Johnson (J&J)—successfully eliminates a minor layer of information asymmetry. Given the decade-long structure of the demerger layout, the top-line revenue has likely been progressively recognized based on historic manufacturing milestones. Thus, investors should view this as a strategic reference boost reinforcing high asset dependability rather than an immediate top-line catalyst for upcoming quarters.
📝 Editor’s Comment (by K-STOCK Editor)
A historic mega-deal from SAMSUNG BIOLOGICS’ early growth days has officially crossed the finish line with flying colors. Initially representing over 4.7 times the firm’s annual sales back in 2016, the contract kept the counterparty anonymous, which is now confirmed to be Cilag, a prominent subsidiary under the J&J corporate umbrella.
The primary takeaway is the exceptionally clean exit. Watching a legacy backlog grow by an extra USD 81 million prior to completion proves that the operational team consistently met the strict purity and scheduling metrics demanded by global Big Pharma. While this closeout won’t inject fresh revenue surprise into upcoming financial statements, adding such a high-profile, successfully completed case study to their active portfolio significantly solidifies institutional investor confidence regarding long-term utilization reliability.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
